Key result
Pulmonary artery banding improves LVEF and fractional shortening in doxorubicin-induced dilated cardiomyopathy.
Why the study?
Does pulmonary artery banding improve ventricular contractile function in a Sprague-Dawley rat model of doxorubicin-induced dilated cardiomyopathy?
Does pulmonary artery banding improve ventricular contractile function in a Sprague-Dawley rat model of doxorubicin-induced dilated cardiomyopathy?
In a pilot rodent study of doxorubicin-induced dilated cardiomyopathy, pulmonary artery banding significantly improved echocardiographic contractile function (ejection fraction and fractional shortening), though model mortality was high.
Answers are grounded in this paper and cite their sources.
Pulmonary artery banding improved contractile function in this rodent doxorubicin model; hypothesis-generating for ventricular rehabilitation and requires clinical validation.
Background: Since 2015, the pulmonary artery banding (PAB), following the Giessen protocol, has treated end-stage heart failure in selected infants with preserved right ventricular function, acting as a bridge to transplant or recovery, as a result of ventricular-ventricular interaction. Objectives: To elucidate whether PAB is a feasible and reproducible procedure in a rodent model of pharmacologically induced dilated cardiomyopathy (DCM) and to evaluate PAB-induced ventricular rehabilitation. Methods: We used 49 Sprague-Dawley rats divided into four groups: a sham surgery control group, a healthy animal group undergoing PAB, a doxorubicin (DOX)- treated control group, and a DOX + PAB-treated group. All underwent echocardiographic, histological, and molecular analyses. Results: Preliminary results showed high mortality in rats with DOX-induced DCM, with contractile dysfunction con fi rmed by 2D echocardiography. Signs of damage were detected through transmission electron microscopy, but not via standard histological/molecular tests. PAB after DOX improved contractile function, enhancing ejection fraction ( p = 0.01) and fractional shortening ( p = 0.03). Conclusion: The DOX-induced DCM model, while reproducible, may not re fl ect DCM ’ s true pathology. High mortality and individual variability limited the study. Further research is needed to fi nd alternative models with lower mortality and to explore the PAB-induced molecular signaling pathways and cardiac proliferation potential
No takes yet. Share an insight, caveat, or question.
Crea et al. (2024) studied Doxorubicin-induced dilated cardiomyopathy (rodent model) (n=49). Pulmonary artery banding (PAB) after doxorubicin-induced cardiomyopathy vs. Doxorubicin-treated control, healthy PAB control, and sham surgery control was evaluated on Left ventricular ejection fraction (EF) via 2D echocardiography (p=0.01). Pulmonary artery banding improved left ventricular ejection fraction and fractional shortening in rats with doxorubicin-induced dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: